Year in Review |
News & Comment
-
-
-
Editorial |
The cost of getting personal
The recent report of an antisense oligonucleotide therapy designed for only one patient spotlights regulatory, economic and ethical issues that must be grappled with in an era of accelerated development of ‘ultra-personalized’ drugs.
-
-
Turning Points |
The community of science
Rachel Ramoni is chief research and development officer for the Department of Veterans Affairs, where she oversees 2,000 active projects at more than 100 sites.
- Rachel Ramoni
-
News Feature |
At the forefront of medical research: our cover authors share their hopes for their fields
From investigating the diversity of the vaginal microbiome to developing neuroprosthetics with sensory feedback for leg amputees, the work of the authors featured in our pages is fascinating. We asked them about their hopes for the future of medical research.
-
-
News Feature |
AI added to the curriculum for doctors-to-be
Medical schools and graduate research programs embrace artificial intelligence.
- Monique Brouillette
-
-
-
-
News Feature |
Looking forward 25 years: the future of medicine
To celebrate the end of our 25th anniversary year, we asked thought leaders and experts in the field to answer one question: What will shape the next 25 years of medical research?
-
Turning Points |
Finding a cure for sickle cell disease
Julie Makani is an associate professor in the Department of Haematology and Blood Transfusion at Muhimbili University of Health and Allied Sciences in Dar es Salaam, where she helped Tanzania establish one of the world’s largest single-center study cohorts for sickle cell disease. She received the 2011 Royal Society Africa Award on the translation of genomics to health benefits.
- Julie Makani
-
News & Views |
Predicting health and life span with the deep plasma proteome
Recent large-scale proteomic studies reveal the association of levels of circulating proteins with life span and many health-related outcomes.
- Valur Emilsson
- , Vilmundur Gudnason
- & Lori L. Jennings
-
-
-
-
Comment |
Academic leadership: (with)holding the keys to translational medicine?
To promote effective translational medicine, academia must take the lead in creating a conducive environment for the first steps into translation, urge Roch Ogier and colleagues.
- Roch Ogier
- , Wolfgang Knecht
- & Martin E. Schwab
-
News & Views |
Transgenerational PCOS transmission
There is a transgenerational increase in the susceptibility of female offspring to developing PCOS that occurs via the female germline and is linked to fetal exposure to excess androgen.
- H. M. Picton
- & A. H. Balen
-
News & Views |
A viral link for type 1 diabetes
Enteroviral infection persistence as determined by host genetic susceptibility, rather than independent, short-lived infections, may contribute to islet autoimmunity and be a precursor to the development of type 1 diabetes.
- Bart O. Roep
-
News & Views |
High-accuracy liquid biopsies
Ultra-deep sequencing of paired plasma-circulating free DNA and white blood cells allows the identification of tumor-derived somatic mutations with high accuracy by filtering out variants consistent with clonal hematopoiesis.
- Beatriz Bellosillo
- & Clara Montagut
-
Comment |
Benefit Corporation: a path to affordable gene therapies?
With the growing number of efficient gene therapies on the market, now is the time to take actions to ensure reasonable pricing of gene therapy products. Among these, we propose to incentivize gene therapy companies to adopt a status that translates their corporate social responsibility into concrete commitments.
- Alain Fischer
- , Mathias Dewatripont
- & Michel Goldman
-
Comment |
Toward a broader response to cardiometabolic disease
Cardiometabolic disease is the leading cause of death and disability in the world, driven in part by the rise in unhealthy diets, poor air quality and other byproducts of economic development. A new economic model is needed, one that places people rather than profits at its center.
- Johanna Ralston
- & Rachel Nugent
-
Editorial |
Untangle food industry influences on health
The rise in cardiometabolic diseases is linked to the availability of unhealthy products from industry, such as ultraprocessed foods, and studying the efficacy of intervention strategies against these products must be high on the research agenda.
-
-
-
-
-
News & Views |
The differing roles of lactobacilli in critical illness
New findings regarding the risks of over-the-counter probiotics in critically ill patients underscore the need for microbiota-targeted therapies that are based on efficacy in a disease- and host-specific context.
- Bastiaan W. Haak
- & W. Joost Wiersinga
-
Turning Points |
The hidden biology of the human brain
Sergiu Pașca is a faculty member at Stanford University, where he is also the Uytengsu Director of the Stanford Brain Organogenesis Program. He is a pioneer in developing 3D brain-region-specific organoids, assembloids and cellular models of neuropsychiatric disease from stem cells.
- Sergiu P. Pașca
-
-
-
-
News & Views |
SGLT-2 inhibitors in heart failure: a new therapeutic avenue
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, reduced the risk of cardiovascular death or heart failure events in 4,744 patients with chronic heart failure with reduced ejection fraction.
- Muthiah Vaduganathan
- & Javed Butler
-
News & Views |
Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer
Activated CD8+ T cells in the tumor and cytotoxic T cell signature correlate with immune response in patients receiving neoadjuvant immunotherapy for treatment of muscle invasive bladder cancer.
- Pooja Ghatalia
- & Elizabeth Plimack
-
News & Views |
An Alzheimer’s-disease-protective APOE mutation
Homozygous APOE3-Christchurch (R136S) mutation protects a presenilin 1 (PSEN1) mutation carrier from developing Alzheimer’s disease until her seventies.
- Kelly A. Zalocusky
- , Maxine R. Nelson
- & Yadong Huang
-
News |
Custom therapies pose huge financial burdens
The development of a custom drugs, like that for Jaci Hermstad’s rare form of ALS, may raise drug costs to new heights.
- Carrie Arnold
-
News |
Bile acids might tip microbiome in healthy direction
Mouse study hints at how bile acid recycling could affect gut bacteria.
- Marcus A. Banks
-
News Feature |
CRISPR-edited babies arrived, and regulators are still racing to catch up
One year after the world learned of He Jiankui’s editing of twins, gaps in rules remain.
- Alisa Opar
-
Correspondence |
A critical analysis of the neurodevelopmental and neurosensory outcomes after 2 years for children with in utero Zika virus exposure
- Manon Vouga
- , Léo Pomar
- , Alice Panchaud
- , Didier Musso
- & David Baud
-
Correspondence |
Reply to ‘A critical analysis of neurodevelopmental and neurosensory outcomes after 2 years for children with in utero Zika virus exposure’
- Karin Nielsen-Saines
- , Patricia Brasil
- , Tara Kerin
- , Zilton Vasconcelos
- , Claudia Raja Gabaglia
- & Maria Elisabeth Moreira
-
Correspondence |
Reply to ‘Simpson’s paradox in proof-of-concept studies’
- Patrice D Cani
- & Clara Depommier
-
Correspondence |
Simpson’s paradox in proof-of-concept studies
- Sok-Ja Janket
- , Leland K Ackerson
- & Eleftherios Diamandis
-
News |
Artificial intelligence aims to improve cancer screenings in Kenya
A handheld microscope sends images from cervical samples to the cloud for analysis.
- Nicole Wetsman
-
-
News & Views |
Microneedle patch drug delivery in the gut
A novel oral capsule can deploy microneedle patches that release drugs into the intestinal wall for uptake into the bloodstream as shown in animal studies, thereby avoiding injections.
- Mark R. Prausnitz
- , Yasmine Gomaa
- & Wei Li
-
Editorial |
Raising the bar for clinical research
Nature Medicine is taking a comprehensive approach for reporting clinical studies with the aim to increase transparency, promote rigorous reporting standards and engage with the community to meet the challenges of contemporary medicine.
-
News & Views |
Surrogate gene therapy for muscular dystrophy
An engineered truncated gene derived from the dystrophin-related protein (utrophin), prevents pathology without an immune response in an animal model of Duchenne muscular dystrophy (DMD) gene therapy.
- Kay E. Davies
- & Jeffrey S. Chamberlain
-
-
